Drug sensivity score accurately predicts... | American Society of Hematology

Drug sensivity score accurately predicts response to Ven-Aza. The VenEx trial1 procured blood or bone marrow samples from study subjects. Mononuclear cells (MNCs) were obtained from samples, and then subjected to an ex vivo high-throughput drug-sensitivity test in specialized media with 7 drug concentrations in 384-well plates. Multicolor flow cytometry was used to gate on the blasts with labeled antibodies to CD34, CD117, and CD45, with the viability markers 7-aminoactinomycin D and annexin V. Viability was assessed at 48 hours, and a DSS was calculated from the area under the curve (AUC). With a specific cutoff determined for venetoclax, the assay could accurately predict ORR comprised of CR or CRi or morphologic leukemia-free state (MLFS) for DSS above the cutoff or no response for DSS below the cutoff, and OS (longer for DSS above the cutoff than below). The image of the 384-well plate was obtained using iQue Forecyt software (Sartorius).

Drug sensivity score accurately predicts response to Ven-Aza. The VenEx trial¹ procured blood or bone marrow samples from study subjects. Mononuclear cells (MNCs) were obtained from samples, and then subjected to an ex vivo high-throughput drug-sensitivity test in specialized media with 7 drug concentrations in 384-well plates. Multicolor flow cytometry was used to gate on the blasts with labeled antibodies to CD34, CD117, and CD45, with the viability markers 7-aminoactinomycin D and annexin V. Viability was assessed at 48 hours, and a DSS was calculated from the area under the curve (AUC). With a specific cutoff determined for venetoclax, the assay could accurately predict ORR comprised of CR or CRi or morphologic leukemia-free state (MLFS) for DSS above the cutoff or no response for DSS below the cutoff, and OS (longer for DSS above the cutoff than below). The image of the 384-well plate was obtained using iQue Forecyt software (Sartorius).

This Feature Is Available To Subscribers Only